Everything you need to cover Corazyme™ and OREVO Fuels. For interviews, additional assets, or specific inquiries, contact us directly.
A proprietary enzymatic platform that converts municipal wastewater sludge into fossil-identical renewable diesel, SAF, and gasoline. Operates at ambient temperature and pressure. No combustion. No new infrastructure required.
From signed agreement to first fuel production at a pilot facility. The modular unit retrofits to existing wastewater infrastructure — no new construction required.
At commercial module scale (~300K population facility), Corazyme™ produces 505,890 gallons of renewable fuel per year at $0.51–$1.70 per gallon production cost against an $8.78 market price.
The input is wastewater sludge — a material every city generates continuously and currently pays to remove. No food-grade inputs. No agricultural feedstocks. No synthetic fuel dependency.
Corazyme™ is bench-validated with IP secured. Active pilot conversations underway in Minneapolis, Vacaville, and Seattle. DOE SBIR and Industrial Technology Validation grants submitted and pending review.
Raising $10M at a $90M pre-money valuation to fund the first commercial Corazyme™ module deployment. Investor ownership: 10%. 2.5–3 year runway to commercial blueprint.
OREVO Fuels is a biotech infrastructure company that converts municipal wastewater sludge into fossil-identical renewable diesel, SAF, and gasoline using its proprietary Corazyme™ enzymatic platform. The technology integrates with existing wastewater infrastructure to produce drop-in fuel with no new construction, no combustion, and no agricultural inputs — deployable within six months of pilot agreement. OREVO is bench-validated, IP-protected, and currently raising a $10M Series A to fund first commercial module deployment. The company is headquartered in the United States and is actively seeking pilot partners and investors.
For interview requests, fact-checking, photography, or any other press inquiry.